J&J slashes outlook, races to develop coronavirus vaccine

FAN Editor

Johnson & Johnson is cutting its profit expectations for the year as the coronavirus disrupts economies worldwide

Johnson & Johnson, anticipating significant impact from the COVID-19 pandemic, slashed its 2020 sales forecast by billions of dollars and also cut its profit expectations.

It’s one of the first major U.S. corporations to report first-quarter earnings and likely a harbinger of things to come as the outbreak disrupts the global economy.

The world’s biggest health products maker on Tuesday said it now expects 2020 revenue of $77.5 billion to $80.5 billion, down from its January forecast of $85.4 billion to $86.2 billion. It also forecast adjusted earnings per share of $7.50 to $7.90, down from the January forecast of $9 to $9.15 per share.

J&J faces both the prospect of lower sales as much of the world stays home to avoid infection, and higher costs as it races to develop a vaccine against the new coronavirus.

“We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use,” Chief Executive Alex Gorsky said in a statement.

The maker of Tylenol and baby shampoo reported a very strong first quarter, with net income up 55%. But that was largely before the outbreak sent the global economy on a new tangent.

Net income was $5.8 billion, or $2.17 per share. That’s up from $3.7 billion, or $1.39 per share, in 2019′s first quarter.

Earning after adjusting for one-time items came to $6.2 billion, or $2.30 per share, which easily beat Wall Street per-share expectations of $2.03 per share.

J&J, based in New Brunswick, New Jersey, posted revenue of $20.69 billion, which also beat Street forecasts for $19.25 billion.

Total sales in the U.S. jumped 5.6% to $10.7 billion, while sales overseas edged up just 1%, to $9.99 billion.

During the quarter, sales of prescription drugs and consumer health products both were up about 9%, to $11.13 billion and $$3.63 billion, respectively.

But J&J’s medical device and diagnostics segment had revenue drop 8% to $5.93 billion.

That segment is more vulnerable to economic downturns because many of its products are for elective surgery, such as hip and knee replacements. J&J said it expected the pandemic to cause medical procedures to be postponed, hurting its surgery, orthopedics and other businesses.

Last month, J&J applied for U.S. and European Union approval of ponesimod, its experimental treatment of adults with relapsing multiple sclerosis.

Shares jumped about 3% before the opening bell.

Free America Network Articles

Leave a Reply

Next Post

Australian cardinal links corruption to child abuse charges

Cardinal George Pell is linking his fight against corruption in the Vatican with his prosecution in Australia for alleged child sex abuse By ROD McGUIRK Associated Press April 14, 2020, 12:45 PM 4 min read 4 min read Share to Facebook Share to Twitter Email this article CANBERRA, Australia — […]